Actively Recruiting
Repositioning Immunotherapy in VetArans With Lung Cancer
Led by VA Office of Research and Development · Updated on 2026-03-02
25
Participants Needed
7
Research Sites
317 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.
CONDITIONS
Official Title
Repositioning Immunotherapy in VetArans With Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient must have a performance status of 0-1 (ECOG Performance Scale)
- Patient must be a candidate for concurrent chemoradiation
- Unresectable Stage III NSCLC as assessed by investigator or multidisciplinary tumor board assessment
- PD-L1 tumor expression greater than or equal to 1%
- Presence of measurable disease according to RECIST v1.1
- Adequate organ function
- Available tissue (archival FFPE preferred) with adequate tumor content ( 20% tumor cellularity)
You will not qualify if you...
- Active autoimmune disease that has requires immunosuppressive therapy in the previous year
- Uncontrolled primary or acquired immunodeficiency (including HIV)
- Baseline corticosteroid usage (>10 mg prednisone or equivalent daily) aside from supportive medication use
- Tumor with known EGFR, ALK, ROS1, MET or RET mutations/fusions
- Presence of significant comorbidities precluding participation in a clinical study as determined by investigator
- Prior thoracic radiotherapy or prior systemic treatment for stage IIIB/IV NSCLC
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
- Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with informed consent through 180 days after the last dose of trial treatment
- Has a known history of active TB (Bacillus Tuberculosis)
- Has known active Hepatitis B or Hepatitis C
- Has received a live vaccine within 30 days of enrollment
- Known diagnosis of Interstitial Lung Disease
- Inability to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
VA Connecticut Healthcare System West Haven Campus, West Haven, CT
West Haven, Connecticut, United States, 06516-2770
Actively Recruiting
2
VA Central Office, Washington, DC
Washington D.C., District of Columbia, United States, 20420-0001
Actively Recruiting
3
Richard L. Roudebush VA Medical Center, Indianapolis, IN
Indianapolis, Indiana, United States, 46202-2884
Actively Recruiting
4
VA Ann Arbor Healthcare System, Ann Arbor, MI
Ann Arbor, Michigan, United States, 48105-2303
Actively Recruiting
5
Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
Omaha, Nebraska, United States, 68105-1850
Actively Recruiting
6
Michael E. DeBakey VA Medical Center, Houston, TX
Houston, Texas, United States, 77030-4211
Actively Recruiting
7
Richmond VA Medical Center, Richmond, VA
Richmond, Virginia, United States, 23249-0001
Actively Recruiting
Research Team
N
Nithya Ramnath, MD
CONTACT
G
Garth W Strohbehn, MD MSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here